Washington University/Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 10301096
• 负责人: NANCY L BARTLETT
• 金额: $ 7万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-12-01 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10301096
• 关键词: American College of Radiology Imaging Network; Area; Cancer Center; Cancer Control; Clinical Research; Clinical Trials; Collaborations; Communication; Comprehensive Cancer Center; Cooperative Group Program; Development; Diagnostic; Disease; Eastern Cooperative Oncology Group; Fostering; Genomics; Goals; Gynecologic Oncology; Illinois; Institution; Lead; Leadership; Lymphoma; Malignant Neoplasms; Malignant neoplasm of lung; Medical Oncology; Mentorship; Mission; Missouri; Modality; Molecular; Oncology; Patients; Physicians; Play; Positioning Attribute; Principal Investigator; Prognostic Marker; Protocols documentation; Radiation Oncology; Radiology Specialty; Recording of previous events; Research Personnel; Site; Specialist; Therapeutic; Thoracic Oncology; Translational Research; Universities; Uterine Cancer; Washington; anticancer research; base; biobank; cancer therapy; control trial; experience; imaging program; imaging study; improved; malignant breast neoplasm; member; metropolitan; mid-career faculty; molecular imaging; novel; operation; professor; programs; proteogenomics; rare cancer; sarcoma; tool

Project Summary The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) NCTN Lead Academic Participating Site UG1 is to 1) foster scientific leadership and mentorship in the NCTN, 2) participate in the development of NCTN therapeutic, correlative, and cancer control trials, and 3) maintain strong accrual to clinical trials across multiple disease sites, including those that are molecularly driven and those for rare cancers. WU/SCC investigators have a long history of enthusiastic participation in the former cooperative group program and continue to play key roles in the current NCTN program, specifically the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 UG1 co-Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Benjamin Kozower, MD, MPH (Professor, Thoracic Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology), Clifford Robinson, MD (Associate Professor, Radiation Oncology) and Barry A. Siegel, MD (Professor, Radiology). The WU/SCC senior leadership team is composed of three legacy members with extensive cooperative group and NCTN experience (Bartlett, Mutch and Siegel) and two new members (Robinson and Kozower) with experience in NCTN trial development. The entire leadership team is committed to providing guidance for an institution-wide NCTN UG1. WU/SCC has consistently demonstrated robust accrual to NCTN trials, accruing 848 patients between March 2014 and August 2017. During this same interval, 535 patients had biospecimens collected and 58 patients were accrued to advanced imaging studies. The strength of the WU/SCC genomics, proteogenomics, and molecular imaging programs in combination with the large institutional biorepositories position us to make significant and novel contributions to the scientific mission of the NCTN. WU/SCC investigators remain highly invested in NCTN translational and clinical research in AML, lymphoma, lung cancer, breast cancer, sarcoma, uterine cancer, molecular imaging, and radiation oncology. In addition, our large referral base and the substantial increase in new cancer cases seen at our center in the last 5 years will enhance our ability to accrue patients to nearly all disease site protocols, including rare tumors. This institution-wide UG1 will facilitate enhanced communication and collaboration among disease-site, translational, and modality specialists and improve our potential for contributions to the NCTN operation.

项目摘要 拟议的华盛顿大学/现场癌症中心的基本目标 （WU/SCC）NCTN领导学术参与网站UG1是1）促进科学领导力和 NCTN的指导，2）参与NCTN治疗，相关性的发展 和癌症控制试验，以及3）对多种疾病的临床试验保持强大的应计 站点，包括分子驱动的站点和用于稀有癌症的站点。 WU/SCC 调查人员在前合作团体中热情参与的历史悠久 编程并继续在当前NCTN程序中扮演关键角色，特别是联盟 对于肿瘤学的临床试验，ECOG-ACRIN癌症研究组和NRG肿瘤学。 WU/SCC将有5名UG1联合主持调查员，包括高级领导团队 包括医学博士Nancy L. Bartlett（医学肿瘤学教授），Benjamin Kozower，MD，MPH （胸部肿瘤学教授），医学博士David G. Mutch（妇科肿瘤学教授）， 医学博士Clifford Robinson（辐射肿瘤学副教授）和MD的Barry A. Siegel （放射学教授）。 WU/SCC高级领导团队由三个遗产组成 拥有广泛合作小组和NCTN经验的成员（Bartlett，Mutch和Siegel） 还有两个新成员（鲁滨逊和科佐尔）在NCTN试验开发方面具有经验。 整个领导团队致力于为整个机构的NCTN提供指导 UG1。 WU/SCC始终证明了NCTN试验的强大应计算，848 2014年3月至2017年8月之间的患者。在相同的间隔中，有535名患者有 收集的生物测量和58例患者被累积到高级成像研究中。这 WU/SCC基因组学，蛋白质组学和分子成像程序的强度 结合大型机构生物关注者，我们将重要而新颖 对NCTN的科学任务的贡献。 WU/SCC调查人员仍然很高 投资于AML，淋巴瘤，肺癌，乳房的NCTN转化和临床研究 癌症，肉瘤，子宫癌，分子成像和放射肿瘤学。另外，我们的 大型推荐基础和我们中心的新癌症病例的大幅增加 最近5年将增强我们吸引患者几乎所有疾病部位方案的能力， 包括稀有肿瘤。该机构范围内的UG1将有助于增强的沟通和 疾病现场，转化和方式专家之间的合作，并改善我们的 潜力为NCTN操作贡献。